Ligands of Immunopharmacology

BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC 50 of  59.1 nM for human TLR7 . BBIQ is a powerful vaccine adjuvant that enhances innate immune responsesIn VitroBBIQ induces IFN-α in

BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC 50 of  59.1 nM for human TLR7 . BBIQ is a powerful vaccine adjuvant that enhances innate immune responsesIn VitroBBIQ induces IFN-α in

BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC 50 of  59.1 nM for human TLR7 . BBIQ is a powerful vaccine adjuvant that enhances innate immune responsesIn VitroBBIQ induces IFN-α in

BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC 50 of  59.1 nM for human TLR7 . BBIQ is a powerful vaccine adjuvant that enhances innate immune responsesIn VitroBBIQ induces IFN-α in

BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cellsIn VitroBMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity

BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cellsIn VitroBMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity

BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cellsIn VitroBMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity

BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cellsIn VitroBMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity

BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cellsIn VitroBMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity

BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cellsIn VitroBMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity

BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1 , with an IC 50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect

BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1 , with an IC 50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect